Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | What to look out for at ASH 2019: MPNs

Mary Frances McMullin • 15 Nov 2019
MPN Advances Day 2019
Myeloproliferative Neoplasms Ropeginterferon alfa-2b

Mary Frances McMullin, MD, Queen’s University Belfast, Belfast, UK, highlights the ropeginterferon alfa-2b treatment for polycythemia vera (PV) clinical trial data she is expecting to be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition 2019. Prof. McMullin discusses the myeloproliferative neoplasms (MPNs) education session on diagnostic workflow for hereditary erythrocytosis and thrombocytosis. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

More from Mary Frances McMullin

1:32
Hereditary erythrocytosis
Mary Frances McMullin • 25 Oct 2021
1:27
Driver mutations in MPNs
Mary Frances McMullin • 25 Oct 2021
3:02
Updated BSH guidelines for non-clonal polycythemia
Mary Frances McMullin • 15 Nov 2019
0:55
The effect of vorinostat on methylation age in MPN patients
Mary Frances McMullin • 15 Nov 2019

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals